The Journal of Contemporary Dental Practice

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 21 , ISSUE 12 ( December, 2020 ) > List of Articles


Angiotensin-converting Enzyme 2 Specific Cell Subset Identification in Oral Tissues: A Need of the Hour in COVID-19 Research

Gargi S Sarode, Amol R Gadbail, Shailesh Gondivkar

Citation Information : Sarode GS, Gadbail AR, Gondivkar S. Angiotensin-converting Enzyme 2 Specific Cell Subset Identification in Oral Tissues: A Need of the Hour in COVID-19 Research. J Contemp Dent Pract 2020; 21 (12):1305-1306.

DOI: 10.5005/jp-journals-10024-2943

License: CC BY-NC 4.0

Published Online: 13-04-2021

Copyright Statement:  Copyright © 2020; The Author(s).


  1. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271–280.e8. DOI: 10.1016/j.cell.2020.02.052.
  2. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203(2):631–637. DOI: 10.1002/path.1570.
  3. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020;12(1):8. DOI: 10.1038/s41368-020-0074-x.
  4. TMPRSS2 and ACE2 coexpression in SARS-CoV-2 salivary glands infection. J Dent Res 2020(10):22034520933589 10.1177/0022034520933589.
  5. Physiology, pathology and regeneration of salivary glands. Cells 2019;8(9):976. DOI: 10.3390/cells8090976.
  6. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 2020;181(5):1016–1035.e19. DOI: 10.1016/j.cell.2020.04.035.
  7. Antimicrobial defence mechanisms of the human parotid duct. J Anat 2006;208(5):609–619. DOI: 10.1111/j.1469-7580.2006.00567.x.
  8. Critical appraisal on salivary diagnostic for COVID-19. Oral Oncol 2020;108:104926. DOI: 10.1016/j.oraloncology.2020.104926.
  9. Perspective on oral exfoliative cytology and COVID-19. Oral Oncol 2020;107:104858. DOI: 10.1016/j.oraloncology.2020.104858.
  10. Patients with interferon expressing oral pathologies are susceptible to COVID-19 infection. Med Hypotheses 2020;144:110179. DOI: 10.1016/j.mehy.2020.110179.
  11. Oral submucous fibrosis and COVID-19: perspective on comorbidity. Oral Oncol 2020;107:104811. DOI: 10.1016/j.oraloncology.2020.104811.
  12. EMMPRIN/BASIGIN as a biological modulator of oral cancer and COVID-19 interaction: Novel propositions. Med Hypotheses 2020;143:110089. DOI: 10.1016/j.mehy.2020.110089.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.